Eicosapentaenoic Acid CAS:10417-94-4

Eicosapentaenoic Acid

Chemical Name: Eicosapentaenoic Acid
Synonyms:all cis-5,8,11,14,17-Eicosapentaenoic Acid
Ropufa 70
TIMNODONIC ACID
eicosapentenoic acid
 
CAS.NO: 10417-94-4
Molecular Formula: C20H30O2
Molecular Weight: 302.45100
 
Physical and Chemical Properties:
Density: 0.941 g / cm3
Boiling point: 439.3ºC at 760 mmHg
Melting point: -54–53ºC (lit.)
Flash point: 336ºC
Refractive index: n20 / D 1.4977 (lit.)
 
Specification:
Appearance: liquid
Purity:≥99%
 
Packing:1kg / 5KG / aluminum bottle, filled with nitrogen
Storage:-20 ° C refrigerated, sealed, dry place
Application:EPA has the effects of lowering blood lipids, lowering blood pressure and lowering blood sugar, and can prevent and improve arteriosclerosis and prevent hypertension. However, in the prevention and treatment of cardiovascular diseases, side effects such as gastrointestinal upset, pulmonary embolism, skin reactions, and agranulocytosis may occur.



We are professional Eicosapentaenoic Acid manufacturer and eicosapentenoic acid supplier in China, We offer quality Ropufa 70 you can fully trust, also we have India factory and producer of eicosapentenoic acid,Pls send inquiry of eicosapentenoic acid CAS:10417-94-4 to info@nbinno.com if you have any interests, thank you!


Related News: Pharmaceutical intermediates: chemical raw materials or chemical products used in the process of pharmaceutical synthesis, are intermediate products in the process of producing APIs, and can be further processed into APIs.2-acetyl-5-methylfuran Pharmaceutical intermediates: chemical raw materials or chemical products used in the process of pharmaceutical synthesis, are intermediate products in the process of producing APIs, and can be further processed into APIs.Triethylsilane CAS:617-86-7 Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).6-Chloro-9-(tetrahydropyran-2-yl)purine Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).“Administrative Measures for the Joint Review, Review and Approval of Raw Materials, Medicinal Auxiliaries and Pharmaceutical Packaging Materials and Pharmaceutical Preparations” (Consultation Draft) issued by the State Food and Drug Administration in December 2017. Supervision departments no longer accept applications for registration of APIs, pharmaceutical excipients, and packaging materials.